Skip to main content Help with accessibility Skip to main navigation

Deucravacitinib

Indication

Deucravacitinib for treating moderate to severe plaque psoriasis

NICE TA 907 - Deucravacitinib for treating moderate to severe plaque psoriasis

 

Red

Brand:

Nice TA:

907

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Skin

Background

1.1 Deucravacitinib is recommended as an option for treating moderate to severe plaque psoriasis in adults, only if:

• the Psoriasis Area and Severity Index (PASI) score is 10 or more and the Dermatology Life Quality Index (DLQI) score is more than 10

• the condition has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated

• the company provides deucravacitinib according to the commercial arrangement

 

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD
BP
CSR
EL
FW
GP
MB
WL
Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 20 - Jul - 2023